Clinical trial

Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

NCT02181101

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention FEC-DocGemzar adjuvant chemotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention FEC-Doc adjuvant chemotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Zoledronic acid i.v. 2 years Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Zoledronic acid i.v. 5 years Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-09-01

PhasePHASE3

Conditions

Breast Neoplasmsunresolved

Interventions

FEC-DocGemzar adjuvant chemotherapyDRUG

FEC-Doc adjuvant chemotherapyDRUG

Zoledronic acid i.v. 2 yearsDRUG

Zoledronic acid i.v. 5 yearsDRUG

Sponsors & collaborators

Ludwig-Maximilians - University of Munichlead sponsor

AstraZenecacollaborator

Chugai Pharma USAcollaborator

Eli Lilly and Companycollaborator

Novartiscollaborator

Sanoficollaborator

Janssen Diagnostics, LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02181101 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.